Literature DB >> 12952304

Neural stem cell biology may be well suited for improving brain tumor therapies.

Stephen Yip1, Karen S Aboody, Michael Burns, Jaime Imitola, John A Boockvar, Jennifer Allport, Kook In Park, Yang D Teng, Mahesh Lachyankar, Tracy McIntosh, Donald M O'Rourke, Samia Khoury, Ralph Weissleder, Peter M Black, William Weiss, Evan Y Snyder.   

Abstract

Neural stem cells (NSCs) are capable of tremendous migratory potential to areas of pathology in the central nervous system. When implanted into a diseased or injured nervous system, NSCs can travel through great distances to and engraft within areas of discrete as well as diffuse abnormalities. Engraftment is often followed by integration into the local neural milieu, accompanied by stable gene expression from the NSCs. In addition, the pluripotency of NSCs endows them with the capability to replace diseased tissues in an appropriate manner. Recent evidence has also suggested that engrafted exogenous NSCs may have effects on the surrounding microenvironment, such as promoting protection and/or regeneration of host neural pathways. These characteristics of NSCs would seem to make them ideal agents for the treatment of various central nervous system pathologies, especially brain tumors. Brain tumors are generally difficult to treat because of the unique location of the lesions. In primary gliomas, the extensive infiltrative nature of the tumor cells presents a challenge for their effective and total eradication, hence the high rate of treatment failure and disease recurrence. In addition, normal brain structures are distorted and are often destroyed by the growing neoplasm. Even with effective therapy to surgically resect and destroy the neoplastic tissues, the brain is still injured, which often leaves the patient in a debilitated state. The unique ability of NSCs to "home in" on tumor cells followed by the delivery of a desired gene product makes the NSC a very promising agent in brain tumor therapy. Cytolytic viruses and genes coding for anti-tumor cytokines, pro-drug converting enzymes, and various neurotrophic factors have all been engineered into engraftable NSCs for delivery to tumors. When they are specially tagged, such injected NSCs can be visualized with the use of novel imaging techniques and tracked in vivo within living animals over real time. If the NSCs were also capable of participating in the subsequent repair and regeneration of the tumor-afflicted brain-at present a potential but as-yet-unproven aspect of this intervention-then its role in abetting anti-tumor therapy would be complete. It is important to emphasize, however, that the use of NSCs is adjunctive and is not a replacement for other therapies that should be used in parallel.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12952304     DOI: 10.1097/00130404-200305000-00007

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  17 in total

1.  Convergence of normal stem cell and cancer stem cell developmental stage: Implication for differential therapies.

Authors:  Shengwen Calvin Li; Katherine L Lee; Jane Luo; Jiang F Zhong; William G Loudon
Journal:  World J Stem Cells       Date:  2011-09-26       Impact factor: 5.326

Review 2.  Stem cell transplantation in brain tumors: a new field for molecular imaging?

Authors:  Nora Sandu; Bernhard Schaller
Journal:  Mol Med       Date:  2010-06-30       Impact factor: 6.354

3.  NEURO-ONCOLOGIC PHYSICAL THERAPY FOR THE OLDER PERSON.

Authors:  Willie Ching; Melissa Luhmann
Journal:  Top Geriatr Rehabil       Date:  2011-07-01

Review 4.  Applications of neural and mesenchymal stem cells in the treatment of gliomas.

Authors:  Thomas Kosztowski; Hasan A Zaidi; Alfredo Quiñones-Hinojosa
Journal:  Expert Rev Anticancer Ther       Date:  2009-05       Impact factor: 4.512

Review 5.  Concise review: Nanoparticles and cellular carriers-allies in cancer imaging and cellular gene therapy?

Authors:  Catherine Tang; Pamela J Russell; Rosetta Martiniello-Wilks; John E J Rasko; Aparajita Khatri
Journal:  Stem Cells       Date:  2010-09       Impact factor: 6.277

6.  Neuronally expressed stem cell factor induces neural stem cell migration to areas of brain injury.

Authors:  Lixin Sun; Jeongwu Lee; Howard A Fine
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

7.  Chemokines regulate the migration of neural progenitors to sites of neuroinflammation.

Authors:  Abdelhak Belmadani; Phuong B Tran; Dongjun Ren; Richard J Miller
Journal:  J Neurosci       Date:  2006-03-22       Impact factor: 6.167

8.  Gene therapy trials for the treatment of high-grade gliomas.

Authors:  Adam M Sonabend; Ilya V Ulasov; Maciej S Lesniak
Journal:  Gene Ther Mol Biol       Date:  2007

9.  Targeting of melanoma brain metastases using engineered neural stem/progenitor cells.

Authors:  Karen S Aboody; Joseph Najbauer; Nils Ole Schmidt; Wendy Yang; Julian K Wu; Yuzheng Zhuge; Wojciech Przylecki; Rona Carroll; Peter M Black; George Perides
Journal:  Neuro Oncol       Date:  2006-03-08       Impact factor: 12.300

10.  Iron labeling and pre-clinical MRI visualization of therapeutic human neural stem cells in a murine glioma model.

Authors:  Mya S Thu; Joseph Najbauer; Stephen E Kendall; Ira Harutyunyan; Nicole Sangalang; Margarita Gutova; Marianne Z Metz; Elizabeth Garcia; Richard T Frank; Seung U Kim; Rex A Moats; Karen S Aboody
Journal:  PLoS One       Date:  2009-09-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.